The last patient included in the Dosindygo phase II clinical trial, led by the Lille University Hospital in partnership with Hemerion Therapeutics, was operated on in June 2023.
The last patient included in the Dosindygo phase II clinical trial, led by the Lille University Hospital in partnership with Hemerion Therapeutics, was operated on in June 2023.